Ypsomed sells its diabetes business and grows by over 35%

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 21.05.2025, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trajectory and achieved consolidated sales of CHF 748.9 million in the financial year 2024/25 (prior year: CHF 548.5 million). Adjusted for the divested pen needle and blood glucose monitoring business and other one-off effects, this represents 37.9% growth or CHF 193.0 million, in line with guidance. Reported operating profit (EBIT) was CHF 112.9 million (prior year: CHF 86.2 million). Adjusted for one-off effects, EBIT in line with guidance reached CHF 140.5 million, representing 42.5% growth. Net profit increased by CHF 9.1 million to CHF 87.5 million (prior year: CHF 78.4 million). Ypsomed has signed an agreement to sell its Diabetes Care business and will now concentrate on expanding its leading position in the Delivery Systems business.

Read more...

Ypsomed sells its diabetes care business to TecMed AG to become a pure play self-injection specialist

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX:YPSN) and TecMed AG (TecMed) have entered into an agreement for the sale of Ypsomed diabetes care business for up to CHF 420 million, including earn-out. TecMed is a company based in Burgdorf, controlled by Willy Michel. Ypsomed is focusing on strengthening its leading position in the market for subcutaneous self-injection solutions for pharmaceutical and biotech companies.

Read more...

Ypsomed and Sidekick Health ​launch a collaborative​ digital health solution for obesity management

Ypsomed and Sidekick Health ​launch a collaborative​ digital health solution for obesity management

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) and Sidekick Health are ​launching​ a​n integrated​ digital health solution to better support people with obesity. Ypsomed's autoinjectors ​seamlessly integrate into​ Sidekick’s​ digital health and chronic condition support​ app to help patients using GLP-1-based injectable therapies manage their treatment more effectively.

Topics:
Innovation & Digital Health

Read more...

A time capsule was placed in the cement base when the foundation stone of Schwerin 2 was laid.

Start of construction on second production facility in Schwerin

Press Releases Ypsomed Group

Burgdorf – With a formal groundbreaking ceremony yesterday, Ypsomed officially launched the construction of its second production facility in Schwerin. As part of the “Schwerin 2” project, the site will be expanded over the coming years in two phases. With this expansion, the company is increasing its production capacity to meet the growing global demand for high-quality selfcare medical technology products.  

Read more...

Ypsomed and CamDiab launch mylife Loop on iOS

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN), together with CamDiab, is launching the iOS version for the mylife CamAPS FX app, which is part of the automated insulin delivery system (AID) mylife Loop. This allows people with type 1 diabetes to easily and discreetly manage mylife Loop on their iPhones. The rollout of mylife Loop on iOS will begin on 24 March 2025 in Sweden and will subsequently be expanded to other countries.

Topics:
Innovation & Digital Health

Read more...